Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cyllene Therapeutics

Request full access

Non-replicating HSV-1 gene therapy for neurological diseases.

Paris, FranceFounded 2019Biotech & Life Sciences

About Cyllene Therapeutics

Cyllene Therapeutics, formerly known as EG 427, is a biotechnology company developing gene therapies for neurological diseases. Founded in 2019 by Philippe Chambon, François Giuliano, and Alberto Epstein, the company is headquartered in Paris, France. The firm's name changed to Cyllene Therapeutics in July 2026 to coincide with a €33 million Series C financing round, honoring the mythical birthplace of Hermes, the namesake of its core technology platform.The company's proprietary HERMES platform utilizes a non-replicating Herpes Simplex Virus type 1 (nrHSV-1) vector. This vector is engineered to deliver disease-modifying transgenes with high precision to targeted neurons in the peripheral and central nervous systems, offering durable gene expression without viral replication. The technology originated from the Elpis project at the END-ICAP laboratory, a joint effort of Université Paris-Saclay, UVSQ, and Inserm.Cyllene's lead asset, EG110A, is a gene therapy candidate for treating severe neuro-urology conditions, specifically neurogenic detrusor overactivity (NDO), a bladder dysfunction common in patients with spinal cord injuries. EG110A is designed to selectively silence the type C sensory neurons responsible for bladder overactivity while preserving normal function. The treatment is administered via injection into the bladder wall. Following IND clearance from the US FDA in June 2024, the company initiated a Phase 1/2 study in the United States. Recent clinical data has shown significant and sustained reductions in urinary incontinence episodes. The company plans to start a pivotal Phase 2b/3 study in 2027 and is also exploring EG110A for overactive bladder (OAB).Cyllene's business model is centered on research and development, funded through venture capital. The company has raised over USD 50 million, including a €27 million Series B in 2025 and a €33 million Series C in 2026. Key investors include GordonMD Global Investments, Merck Ventures, Andera Partners, and Bpifrance. The company's strategy involves advancing its candidates through clinical trials to demonstrate value, with the long-term goal of either partnering with larger pharmaceutical firms or commercializing the therapies independently. Beyond urology, Cyllene is expanding its pipeline to address other neurological indications, such as chronic pain and migraine.

Source: Dealroom company data

At a glance

Status
Operational
Employees
25
Open positions
None listed
Dealroom signal
82.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Genetics and genomics, Precision Medicine, Gene Therapy, Spinout, Genome Engineering, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Seal of Excellence EC
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jul 2026 $36M $145M Bpifrance · M Ventures · Andera Partners · GordonMD Global Investment ↗
SERIES BOther financing Feb 2025 $30M $119M SCI Ventures · Andera Partners · Bpifrance ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Cyllene Therapeutics website traffic

Latest recorded traffic for Cyllene Therapeutics is 2.2K monthly website visits, up 83.3% over the last three months. Cyllene Therapeutics's team declined 3.8% over the past year.

Latest monthly visits2.2K 3-month web change+83.3% 1-year team growth-3.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cyllene Therapeutics in the Paris ecosystem

Live from Dealroom

The Cyllene Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later2 investors entered at this stage

  • M Ventures
  • GordonMD Global Investment

Other known investors6 additional known investors

  • Assistance Publique - Hôpitaux de Paris
  • INSERM
  • Paris-Saclay University
  • SATT Paris-Saclay
  • University of Versailles Saint-Quentin-en-Yvelines - Paris-Saclay University
  • Paris Biotech Santé
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇫🇷 France100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cyllene Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cyllene Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.